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Abstract
Microarray-based gene expression analysis holds promise of improving prognostication and treatment decisions for breast
cancer patients. However, the heterogeneity of breast cancer emphasizes the need for validation of prognostic gene
signatures in larger sample sets stratified into relevant subgroups. Here, we describe a multifunctional user-friendly online
tool, GOBO (http://co.bmc.lu.se/gobo), allowing a range of different analyses to be performed in an 1881-sample breast
tumor data set, and a 51-sample breast cancer cell line set, both generated on Affymetrix U133A microarrays. GOBO
supports a wide range of applications including: 1) rapid assessment of gene expression levels in subgroups of breast
tumors and cell lines, 2) identification of co-expressed genes for creation of potential metagenes, 3) association with
outcome for gene expression levels of single genes, sets of genes, or gene signatures in multiple subgroups of the 1881-
sample breast cancer data set. The design and implementation of GOBO facilitate easy incorporation of additional query
functions and applications, as well as additional data sets irrespective of tumor type and array platform.
Citation: Ringne ´r M, Fredlund E, Ha ¨kkinen J, Borg A ˚, Staaf J (2011) GOBO: Gene Expression-Based Outcome for Breast Cancer Online. PLoS ONE 6(3): e17911.
doi:10.1371/journal.pone.0017911
Editor: Chad Creighton, Baylor College of Medicine, United States of America
Received December 23, 2010; Accepted February 14, 2011; Published March 21, 2011
Copyright:  2011 Ringne ´r et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The present study was supported by the Swedish Cancer Society, the Foundation for Strategic Research through the Lund Strategic Centre for
Translational Cancer Research (CREATE Health), and the Swedish Research Council. The funders had no role in study design, data collection and analysis, decision
to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: johan.staaf@med.lu.se
Introduction
Breast cancer is one of the most common malignancies in the
world. It is evident that breast cancer is a heterogeneous disease
characterized by different tumor biological and histological
subtypes, age of onset, clinical course and responsiveness to
treatment. Although currently used prognostic and treatment-
predictive markers for breast cancer have markedly improved
treatment decisions, additional markers are required to further
tailor treatment for individual patients.
Microarray-based gene expression profiling has been used
extensively to characterize the transcriptome of breast cancer,
resulting in the identification of new molecular subtypes and
markers or signatures of potential therapeutic and prognostic
importance [1–12]. Although microarray-based gene expression
profiling of breast carcinoma holds promise for future improvement
in treatment decisions, current studies aimed at deriving prognostic
or treatment predictive gene signatures are often limited by a low
number of included patients, typically tens to hundreds, due to cost
and availability of suitable tissue specimens. The growing
accumulation of data from prognostic and/or treatment predictive
gene expression studies on breast cancer in public repositories, e.g.
Gene Expression Omnibus [13], provides an opportunity to
construct pooled gene expression data sets comprising a larger
number of patients with sufficient clinical data. Pooled gene
expression data sets of different sizes have been used for prognostic
validation of single and multigene predictors [14–17], identification
of gene set modules associated with prognosis [7,18–20], distinction
of clinical types of breast cancer [21], and dissection of underlying
processes in reported prognostic predictors [19,22]. Although data
sets in larger pooled sets are often individually available through
public repositories, the combined pooled data sets are commonly
not available, thereby representing an obstacle to researchers with
limited bioinformatic resources. To address this latter shortcoming,
we developed Gene expression-based Outcome for Breast cancer
Online (GOBO). GOBO is aimed at providing an online tool for
prognostic validation of single genes, sets of genes or simple
predictors in a pooled breast cancer data set comprising 1881 cases
from eleven public data sets analyzed using Affymetrix U133A
arrays. In addition, GOBO allows online investigation of the
expression of single genes or sets of genes across a large set of
commonly used breast cancer cell lines [23], as well as identification
of co-expressed genes in both breast cancer cell lines and breast
tumors. Using the CCNB1 gene and a Core Serum Response gene
signature as two examples we illustrate the usefulness of GOBO for
rapid online analysis in a large breast cancer data set
Results
Overview of GOBO applications
The web interface of GOBO allows precompiled data sets to be
queried by the three main applications of GOBO: Gene Set
Analysis (GSA), Co-expressed Genes (CG), and Sample Prediction
(SP) (Figure 1). Currently, the precompiled data sets consist of gene
expression data and annotation data for a pooled 1881-sample
breast tumor set and 51 previously reported breast cancer cell lines
[23]. The 1881-sample breast tumor set comprises 11 public data
sets (Table 1) analyzed using Affymetrix U133A arrays and
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into outcome analysis in breast tumors (GSA-Tumor) and
expression patterns in breast cancer cell lines (GSA-Cell line). In
both GSA applications the input is either a single gene or probe
identifier, or a set of gene/probe identifiers (referred to as a gene set
hereinafter). CG allows identification of co-expressed genes by
provision of a single gene identifier in both the breast tumor data set
and the panel of breast cancer cell lines. SP allows users to
investigate the association of their classifiers (in certain predefined
forms) with outcome in the 1881-sample breast cancer set.
Pooling of gene expression data sets generated at different
institutions and time points may introduce artifacts due to, e.g.,
Figure 1. Architecture of GOBO. (A) Flowchart of the GOBO software illustrating the three different modules, data set module (black), web
interface module (red) and analysis module (blue). (B) Layout of GOBO applications with respect to input and results generated.
doi:10.1371/journal.pone.0017911.g001
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sample selections and laboratory practices. To investigate whether
such data set related artifacts existed in the 1881-sample set we
undertook three investigations. First, we performed principal
component analysis (PCA) and analyzed associations between
principal components and a variety of sample annotations (Figure
S1 in File S2). We observed that the different data sets are
contributing variation, however, in combination with biological/
clinical features. Importantly, the first three components are
significantly associated with molecular subtypes, ER status,
histological grade and lymph node status. Since some of the
included data sets contain only ER-negative, ER-positive or node
negative tumors, respectively, variation associated with data sets
cannot be corrected for without the risk of deleteriously affecting
biological/clinical features. Second, we examined gene expression
levels of Affymetrix probes suggested from literature to provide high
sensitivity and specificity in assigning cases to clinical subtypes based
on ERand HER2-status. Expression levelswere investigatedinnine
of eleven data sets for samples stratified by ER-status and PAM50
gene expression subtype classes (Figures S2 to S4 in File S2). These
analyses show consistency across data sets in the expression of ER
and HER2 across samples clinically annotated with ER-status, as
well as in what would be expected for the PAM50 gene expression
subtypes. Finally, we performed hierarchical clustering of the 1881-
sample data set using the PAM50 gene set [24], showing that the
different data sets are intermixed (Figure S5 in File S2). Taken
together, these validations indicate that the 1881-sample set can be
used for the types of supervised analyses made available through
GOBO. Moreover in the GOBO applications, we provide analysis
that reveals the influence of each data set on the result.
Association of gene sets with breast cancer outcome
(GSA-Tumor)
Numerous studies have investigated the prognostic importance
of mRNA expression, as measured by microarrays or quantitative
PCR, from single genes or sets of genes in different breast cancer
subgroups [14,18,19,25]. An online tool was recently reported that
allows Kaplan-Meier survival analysis of single genes in a pooled
1809-sample microarray-based breast cancer data set [26]. The
GSA-Tumor application of GOBO extends on the application
reported by Gyorffy et al. [26] by allowing: 1) expression of gene
sets to define patient cohorts based on a larger number of
quantiles, 2) gene weights to be used in computation of a
combined expression score, 3) time-censoring, 4) multivariate
analysis of gene expression groups with other covariates such as
estrogen receptor (ER) status, lymph node (LN) status, histological
grade, stratified tumor size (#20 mm or .20 mm), stratified
patient age (#50 years or .50 years), 5) analysis of gene set
expression across clinical (ER, LN, and histological grade) and
molecular breast cancer subgroups [1,24], and 6) correlation of
expression of individual genes in a gene set with co-expressed gene
modules emulating breast cancer specific biological processes
(Fredlund et al., Manuscript in preparation).
In GSA-Tumor a gene set comprises either a single or multiple
genes. Weights can be associated with each gene, thus allowing
genes with positive and negative relative expression levels to be
combined into a gene set. In the case of multiple genes an averaged
gene set expression (including weights if supplied) is computed, prior
to dividing the data set into patient cohorts based on gene
expression quantiles. Association with outcome is investigated for
stratified patient cohorts using distant metastasis-free survival
(DMFS), relapse-free survival (RFS) or overall survival (OS) in
different breast cancer subgroups. GSA-Tumor allows division of
the 1881-sample data set intofivemajor subgroups based on clinical
annotations available from GEO [13]; 1) all 1881 tumors, 2) ER-
positive tumors (n=1225), 3) ER-negative tumors (n=395), 4)
systemically untreated patients (n=927), and 5) patients treated
withtamoxifen alone (n=326, GSE6532 [27] and GSE12093[28]).
In each of the selected major subgroups, survival analysis including
Kaplan-Meier,univariateandmultivariateanalysis,isperformedon
subsequently more stratified groups based on gene expression
subtypes (basal-like, HER2-enriched, luminal A, luminal B,normal-
Table 1. Clinical characteristics of individual data sets in the combined 1881-sample Affymetrix U133A data set.
GEO ID
Number
of
samples
ER:
2/+
A
LN:
2/+
B
DMFS
(0/1)
C
Average
DMFS
(years)
OS
(0/1)
D
Average
OS
(years)
RFS
E
(0/1)
Average
RFS
(years)
Grade:
1/2/3
Median
age
(years)
Average
size
(mm) Reference
GSE7390 198 64/134 198/0 136/62 10.865.4 142/56 11.463.7 107/91 9.365.6 30/83/83 46672 2 68 [50]
GSE3494 251 34/213 158/84 NA NA 132/119 7.964.1 155/96 5.563.4 67/128/54 64614 22613 [51]
GSE1456 159 29/130 94/60 NA NA 119/40 6.461.9 119/40 6.262.3 28/58/61 56614 22612 [52]
GSE2034 286 77/209 286/0 179/107 6.563.5 NA NA NA NA 6/42/139* 53612* 1066* [6]
GSE2603 99 42/57 34/65 55/27 5.262 . 3 N AN AN AN A N A 5 6 614 36617 [53]
GSE6532 327 45/262 221/85 225/68 6.363.7 NA NA 195/111 6.363.7 65/145/60 60.5612 23612 [27]
GSE4922 40 NA NA NA NA NA NA NA NA 0/40/0 NA NA [36]
GSE12093 136 0/136 136/0 116/20 7.763.2 NA NA NA NA NA NA NA [28]
GSE5327 58 58/0 NA 47/11 6.863.1 NA NA NA NA NA NA NA [54]
GSE11121 197 NA 197/0 153/44 7.864.2 NA NA NA NA 29/135/33 NA 21610 [55]
Chin 130 46/84 59/71 102/27 5.764 84/45 6.463.7 NA NA 14/46/65 51615 27614 [41]
Total 1881 395/1225 1383/365 1013/366 7.264.2 477/260 8.264.4 576/338 6.764.2 239/677/495 55613 20612
AER: Estrogen receptor.
BLN: Lymph node.
CDMFS: Distant metastasis-free survival.
DOS: Overall survival.
ERFS: Relapse-free survival.
*Collected from publications.
doi:10.1371/journal.pone.0017911.t001
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status (untreated or tamoxifen treated tumors).
Proliferation has been recognized as one of the key prognostic
factors in breast cancer, and has been found to be the major
constituent of several prognostic gene expression signatures
[19,22]. Aberrant cell proliferation requires deregulation of several
cellular functions or pathways, including cell cycle progression.
Cyclins and cyclin-dependent kinases (CDKs) are key regulators of
the cell cycle, controlling the progression and initiation of different
phases of the cell cycle [30]. One of the key components of the
transition between the G2 and M phase in the cell cycle is the
protein complex formed by cyclin B1 (CCNB1) and CDK1 [31].
CCNB1 protein levels have been shown to differ between breast
cancer subgroups [32], tumors of different histological grade
[32,33], and to be associated with breast cancer outcome [32–34].
In addition, CCNB1 is also included in several prognostic gene
signatures such as the 21-gene recurrence score [10] and two
genomic grade signatures [35,36]. Using GSA-Tumor we stratified
the 1881-tumor set into three quantiles based on CCNB1 gene
expression (File S1). GSA-Tumor analysis of CCNB1 gene
expression shows, in agreement with previous protein-based
studies, that elevated expression is associated with the basal-like
and luminal B gene expression subgroups (Figure 2A), higher
histological grade (Figure 2B), and worse clinical outcome
predominantly in ER-positive breast cancers (Figures 2C and D)
supported by multivariate analysis (Figure 2E) [32–34].
Figure 2. GSA-Tumor analysis of CCNB1 using the 1881-sample breast cancer data set. (A) Box plot of CCNB1 gene expression for tumor
samples stratified according to PAM50 subtypes [24]. (B) Box plot of CCNB1 gene expression for tumor samples stratified according to histological
grade. (C) Association with outcome for CCNB1 gene expression levels in subgroups of breast cancer using DMFS as endpoint and 10-year censoring.
Samples in the 1881-sample set were stratified into three quantiles based on CCNB1 expression, CCNB1_low (log2 expression 22.9 to 20.497),
CCNB1_medium (20.48 to 0.416), and CCNB1_high (0.42 to 2.8) followed by Kaplan-Meier survival analysis in 21 subgroups for 1379 cases with DMFS
follow-up. Logrank P-values are shown as 2log10(P-value). (D) Kaplan-Meier analysis, using DMFS as endpoint, for ER-positive tumors (n=856)
stratified into the three quantiles based on CCNB1 gene expression level. (E) Corresponding multivariate analysis for ER-positive tumors (n=554)
using lymph node status and stratified histological grade (histological grade 1 and 2 vs. 3) as covariates and DMFS as endpoint with 10-year
censoring.
doi:10.1371/journal.pone.0017911.g002
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line)
Cancer cell lines, derived from immortalized cancer cells, are
commonly employed in cancer research as model systems for
functional assessment of aberrant gene function and prediction or
indication of response to therapeutic substances. Furthermore, it
has been shown that breast cancer cell lines in many aspects
mirror the heterogeneity in transcriptional and genomic aberra-
tions found in breast tumors [23,37], underlining the importance
of selecting the appropriate cell line for a specific experiment. The
GSA-Cell line application provides an interface for exploring
mRNA expression levels of gene sets across 51 previously reported
breast cancer cell lines [23], reporting both relative gene
expression levels across the cell line panel, as well as summarized
average intensity values. Similarly as for GSA-Tumor, if a gene set
consists of multiple genes an average expression is computed for
the total gene set, taking consideration to gene weights if supplied.
Using the GSA-Cell line application, we investigated CCNB1
mRNA expression levels across the breast cancer cell line panel.
Highest gene expression was observed in the basal B subgroup
associated with a more stem-cell like phenotype and recently also
the claudin-low subtype [23,38], followed by the basal A and
luminal subgroups as defined by Neve et al. [23] (Figures 3A and
B). In line with previous reports analyzing CCNB1 protein
expression we found that triple-negative cell lines displayed highest
CCNB1 mRNA expression levels (Figure 3C) [32].
Co-expressed Genes
Utilization of gene expression microarrays has made it clear that
for a given gene investigated in a large enough data set other genes
exist that display high similarity in expression pattern across
samples. This co-expression of multiple genes is anticipated, given
that functional processes and molecular pathways in an organism
involve a highly organized interplay between multiple genes.
Moreover, the co-expression of genes suggests that genes in a gene
signature are often interchangeable as illustrated in a reanalysis of
the van’t Veer et al. [12] data set [39], indicating that it is the
functional processes captured by a gene signature and not the
individual genes that is of importance [22]. Recently, the approach
of constructing metagenes or gene expression modules aimed at
mimicking key biological processes in breast cancer has been
utilized to identify gene sets with prognostic or treatment
predictive power in breast cancer subgroups [4,18,19,40]. These
metagenes or gene expression modules are often based on
identification of co-expressed genes to a specific prototype gene
believed to represent the biological process of interest.
The CG application of GOBO allows single genes to be used as
prototype genes for identification of co-expressed genes by Pearson
or Spearman correlation analysis in both subsets of the breast
tumor data set (similar as GSA-Tumor) and the breast cancer cell
line data set. The list of co-expressed genes can be further
submitted to iterative correlation analysis, identifying which of the
co-expressed genes that show tight co-expression with each other
in an iterative process across the selected data set. The result of
such an analysis could be a smaller cluster of genes that all are
highly correlated with each other, representing a more distinct
metagene or gene module (Fredlund et al., Manuscript in
preparation). Using the CG application, we searched for genes
highly co-expressed with CCNB1 in a 1751-sample subset of the
1881-sample breast cancer data set (excluding Chin et al. [41]
cases) (File S1). Using a Pearson correlation cut-off .0.6 combined
with a gene expression log2 standard deviation cut-off .0.9, we
identified 34 genes to be positively co-expressed with CCNB1
(Table S1). When subjected to iterative correlation analysis one by
one, all 35 genes showed at least 5 connections (Pearson
correlation .0.6) with other highly co-expressed genes
(Figure 4A, visualized using Cytoscape [42]). Functional analysis
of the 35 genes using DAVID [43,44] confirmed the strong
association with cell cycle processes, specifically M-phase and
mitosis (Table S2). CCNB1 mRNA expression has been reported to
be significantly and positively correlated with mRNA expression
levels of CENPE, AURKB, PLK1, and PLK4 in both breast tumors
and breast cancer cell lines [32]. None of these genes were present
in the list of 34 genes from the CG analysis, explained by lower
correlations (CENPE: 0.47, AURKB: 0.42, PLK1: 0.39, PLK4 0.38)
to CCNB1 in our analysis. However, when performing a CG
analysis in the Neve et al. cell line panel we found PLK1, AURKB
and CENPE to be correlated (Pearson correlation .0.5) with
CCNB1 given a gene expression log2 standard deviation cut-off
.0.4. Association with outcome for a derived co-expressed gene
set may be further investigated by subsequent GSA-Tumor or SP
analysis (Figure 4B, File S1), while association with biological
processes could be made through usage of public functional
annotation tools.
Sample Prediction
A multitude of microarray-based gene signatures have been
derived stratifying breast cancer into subtypes [1,2,24], identifying
patients at risk [5,6,8,9,11,12], and predicting response to
therapeutic agents [3,4]. However, it has become evident that
gene signatures often represent the same biological processes [22],
are associated with outcome only in subgroups of breast cancer
[18,19], and that validation of gene signatures needs to be
performed in large independent data sets [45]. The SP application
of GOBO is aimed at providing an interface for prognostic
validation of simple gene signatures in similar subsets of the 1881-
sample breast cancer data set as for GSA-Tumor. Currently, SP
supports three forms of predictor designs; 1) PAM-clustering [46],
2) stratification by expression quantiles, and 3) correlative centroid
prediction. SP analysis includes, similar to GSA-Tumor, Kaplan-
Meier analysis, univariate and multivariate analysis of predicted
groups, as well as correlation of predictor genes to functional
modules (Figure 1B).
Cancer invasion and metastasis represent the often-fatal steps in
tumor progression, but remain poorly understood. Clearly,
modifications in the tumor microenvironment involving not only
tumor cells but also surrounding tissue, e.g., tumor-associated
fibroblasts, are required for a tumor to become invasive and able
to metastasize. Observations of histological similarities between the
tumor microenvironment and normal wound healing have led to
the hypothesis that tumors represent ‘‘wounds that do not heal’’
[47]. Fibroblasts represent a key component in wound healing,
and in an attempt to identify a canonical gene expression signature
of the fibroblast serum response to wound healing Chang et al.
[48] reported a Core Serum Response (CSR) signature that was
subsequently found to be associated with outcome in breast cancer
Figure 3. Result of GSA-Cell line analysis for CCNB1. (A) Box plots of CCNB1 gene expression across cell lines grouped in the basal A (red), basal
B (grey) and luminal (blue) subgroups [23]. (B) Expression of CCNB1 across the 51 individual cell lines. Colours according to (a). (C) Box plot of gene
expression for CCNB1 across cell lines grouped into clinical subtypes; triple negative (TN, red), HER2-positive (HER2, purple), and Hormone receptor-
positive (HR, blue) based on annotation data from Neve et al. [23].
doi:10.1371/journal.pone.0017911.g003
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PLoS ONE | www.plosone.org 6 March 2011 | Volume 6 | Issue 3 | e17911Figure 4. Identification of CCNB1 co-expressed genes and their association with outcome as a gene set. (A) GOBO analysis using the Co-
expressed genes application identified 34 genes to be highly correlated with CCNB1 in a 1751-sample subset of the full combined breast cancer data
set (excluding Chin et al. cases). Iterative correlation analysis of the 35 genes showed that all genes were highly correlated to each other with at least
5 connections, as visualized by a Cytoscape V2.6.3 spring embedded network. Each connection is visualized as a line between two genes. CCNB1 is
highlighted in yellow. (B) PAM clustering into two groups of samples using the Sample Predictor (SP) application with the 35 genes in (a), followed by
Kaplan-Meier analysis for 21 subgroups of the 1881-tumor set using DMFS as endpoint and 10-year censoring for 1379 cases with DMFS follow-up.
Logrank P-values are shown as 2log10(P-value).
doi:10.1371/journal.pone.0017911.g004
GOBO: Breast Cancer Outcome Analysis Online
PLoS ONE | www.plosone.org 7 March 2011 | Volume 6 | Issue 3 | e17911Figure 5. Sample Prediction analysis of the CSR gene signature in the 1881-sample breast cancer data set. (A) Composition of CSR
classification groups for different clinical variables and Hu et al. gene expression subtypes in the 1881-sample set. (B) Association of the CSR activated
fibroblast classification group with clinical variables and gene expression subtypes (Hu et al.). Y-axis display log10(P-value) from Fisher tests for each
category. E.g., for the basal-like subtype a 262 table is generated containing number of basal-like tumors in the CSR activated fibroblast class,
number of non-basal-like tumors in the CSR activated fibroblast class, number of basal-like tumors in the CSR non-activated class and number of non-
basal-like tumors in the CSR non-activated class. Fisher P-values from tests with odds ratios ,1 (negative association) are depicted as log10(P)
(negative values on y-axis), whereas odds ratios .1 (positive association) are depicted as –log10(P) (positive values on y-axis). Results can be
interpreted such that the CSR activated fibroblast class is associated with ER-negative tumors, tumors with histological grade 3, and tumors classified
as basal-like or luminal B. (C) Association with outcome for CSR classification in subgroups of breast cancer using DMFS as endpoint and 10-year
censoring. Samples in the 1881-sample set were stratified into two groups based on correlation to the CSR activated fibroblast gene signature,
GOBO: Breast Cancer Outcome Analysis Online
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the CSR signature in subgroups of breast cancer we submitted the
CSR activated fibroblast centroid [8] to SP analysis (File S1).
Analysis of the association for the CSR signature with different
clinical and molecular variables showed that the activated
fibroblast class of tumors was predominantly associated with
typical high-proliferative poor outcome classes in breast cancer,
such as ER-negative tumors, histological grade 3 tumors, basal-like
and luminal B classified tumors (Figure 5A and B). In contrast, the
non-activated fibroblast class of tumors was associated with ER-
positive tumors, histological grade 1 and 2 tumors, luminal A and
normal-like classified tumors (Figure 5A and B). As expected from
these results the CSR signature was associated with outcome for all
tumors (Figure 5C).
SP analysis also reveals if a signature is associated with outcome
within subgroups of breast cancer stratified using clinical and
molecular variables. Association with outcome for the CSR
signature was mainly observed for ER-positive, LN-positive, LN-
negative, untreated tumors, tamoxifen (TAM) alone treated
tumors, or ER-positive/LN-negative tumors (Figure 5C). In
further support, associations with outcome for CSR in ER-positive
(Figure 5D), LN-positive and TAM tumors were supported by
multivariate analysis using ER-status, LN-status and stratified
histological grade as covariates when applicable. Taken together,
the CSR SP and CCNB1 GSA-Tumor analyses are consistent with
results from meta-analyses of different prognostic gene signatures,
including CSR, identifying proliferation as the major constituent
of several signatures [19,22]. These meta-analyses have shown the
signatures to be predominantly associated with outcome in ER-
positive breast cancers, whereas the signatures identify the
majority of ER-negative breast cancers as poor outcome and
cannot be used to further stratify ER-negative tumors into groups
with different outcome. These findings reinforce that prognostic
gene signatures in breast cancer need to be evaluated in a subtype-
specific manner in sufficiently large sample sets [18,19,22,49].
Interestingly, a majority of genes in the CSR centroid did not show
clear co-expression with any of eight different co-expressed gene
expression modules, including two proliferation modules (Check-
point and M-phase) (Fredlund et al. Manuscript in preparation)
(Figure 6A). Moreover, in exploratory analysis we found that genes
in the CSR centroid did not show extensive co-expression when
tested pair-wise in the 1751-sample subset used by the CG
application (Figure 6B). Similarly, when dissecting several reported
gene signatures Wirapati et al. found that when using only a subset
of signature genes associated with proliferation, performance was
identical or even improved for certain signatures [22]. This
observation suggests that many prognostic gene signatures contain
only a smaller fraction of genes actually associated with outcome,
and a significant proportion of passenger genes that may perturb
or even have a detrimental effect on the prognostic performance.
Conclusions
GOBO is a convenient and user-friendly online tool for
preliminary analysis of association with outcome for gene
expression levels of single genes, sets of genes or gene signatures
in a large public breast cancer microarray data set. Moreover,
GOBO offers the possibility of investigation of gene expression
levels in breast cancer subgroups and breast cancer cell lines for
gene sets, as well as creation of potential metagenes based on
iterative correlation analysis to a prototype gene. We have here
demonstrated the usefulness of GOBO using CCNB1 and the CSR
gene signature as two examples for rapid online extraction of gene
expression patterns, co-expressed genes, and survival analysis in a
large breast cancer data set.
followed by Kaplan-Meier survival analysis in 21 subgroups using 1379 cases with DMFS follow-up. Logrank P-values are shown as 2log10(P-value).
(D) Corresponding multivariate analysis for ER-positive tumors (n=554) using lymph node status and stratified histological grade (histological grade 1
and 2 vs. 3) as covariates, DMFS as endpoint and 10-year censoring. ER status is omitted from the multivariate analysis since all investigated cases are
ER-positive.
doi:10.1371/journal.pone.0017911.g005
Figure 6. Correlation of genes in the CSR signature to different
gene modules and pair wise co-expression. (A) For each gene
module and gene in the CSR centroid (n=304 matching), a Spearman
correlation value is computed by comparing the expression pattern
across all samples for a specific gene to the corresponding rank sum for
each sample in the specific module. Red dots indicate actual correlation
values. (B) Box plot of pair wise correlations (n=46056 pairs) of 304
genes from the CSR centroid matching in the 1751-sample set used by
the CG application, showing that the absolute majority of genes in the
CSR gene signature is not co-expressed across a large set of breast
tumors.
doi:10.1371/journal.pone.0017911.g006
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GOBO is designed in three modules; a data set module, a web
interface module, and a data processing module (Figure 1). The
data set module contains normalized gene expression data sets,
and corresponding annotation data compiled into R-data objects.
The GOBO web-interface module is written using Perl CGI. In
the data processing module, application specific Perl scripts are
used to parse parameters passed from web-interface, and to launch
application specific R-scripts for analysis. R-scripts perform all
analyses using standard R packages, such as survival for outcome
analysis. Upon completion, R-scripts return analysis results as files
available from the web-server for download. In order to simplify
extensive analysis comparisons, storage of analysis results and to
provide plots as scalable vector graphics supporting incorporation
in publications output from GOBO analyses are reported as text
and pdf files.
Availability and Future Directions
GOBO is freely accessible from the GOBO website http://co.
bmc.lu.se/gobo. The design and implementation of GOBO
facilitate easy incorporation of additional query functions and
applications, as well as additional data sets irrespective of tumor
type and array platform in the form of precompiled R-data sets.
Future integration of data sets with additional information such as
mutation status, copy number alterations or methylation data may
further enhance the usefulness of GOBO.
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